市場調査レポート

商品コード

1630607

遺伝性血管性浮腫治療薬市場規模、シェア、成長分析、治療法別、投与経路別、流通チャネル別、最終用途別、地域別 - 産業予測、2025-2032年

Hereditary Angioedema Treatment Market Size, Share, Growth Analysis, By Treatment, By Route of Administration, By Distribution Channel, By End Use, By Region - Industry Forecast 2025-2032

出版日: 2025年01月07日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

遺伝性血管性浮腫治療薬の世界市場規模は、2023年に27億米ドルと評価され、2024年の27億7,000万米ドルから2032年には33億7,000万米ドルに成長する見通しで、予測期間（2025-2032年）のCAGRは2.5%です。

そのヘルスケア分野における市場拡大は、希少疾患、特に遺伝性血管性浮腫（HAE）に対する治療の必要性が認識されるようになったことが大きな原動力となっています。この疾患は約50,000人に1人が罹患し、世界の有病率は150,000人に1人です。体の様々な部位の突然の腫れを特徴とする血管性浮腫発作の発生率の増加は、最新の治療選択肢と患者支援を提唱するUS Hereditary Angioedema Associationのような組織による啓発活動の高まりにつながっています。最近の調査によると、医療従事者は遺伝性血管性浮腫管理における進歩を報告しており、新しい治療法によって患者の治療結果と満足度が向上しています。インドでは、推定30,000-50,000人が遺伝性血管性浮腫に苦しんでおり、主に皮膚科医、消化器科医、臨床アレルギー専門医が治療にあたっています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

CSL Behring（Australia）
Takeda Pharmaceutical Company Limited（Japan）
Pharming Group N.V.（Netherlands）
BioCryst Pharmaceuticals, Inc.（USA）
Ionis Pharmaceuticals, Inc.（USA）
Sanofi S.A.（France）
Adverum Biotechnologies, Inc.（USA）
KalVista Pharmaceuticals, Inc.（USA）
Attune Pharmaceuticals, Inc.（USA）
Arrowhead Pharmaceuticals, Inc.（USA）
Amgen Inc.（USA）
BioMarin Pharmaceutical Inc.（USA）
Catalyst Biosciences, Inc.（USA）
RUCONEST（Pharming Group N.V., Netherlands）
Haegarda（CSL Limited, Australia）
Firazyr（Shire plc, UK）
Dyax Corp.（USA）
Adverum Biotechnologies, Inc.（USA）
Amgen Inc.（USA）

結論と推奨事項

Product Code: SQMIG35J2031

Global Hereditary Angioedema Treatment Market size was valued at USD 2.7 billion in 2023 and is poised to grow from USD 2.77 billion in 2024 to USD 3.37 billion by 2032, growing at a CAGR of 2.5% during the forecast period (2025-2032).

Market expansion in the healthcare sector is significantly driven by the growing recognition of the need for treatments for rare disorders, notably hereditary angioedema (HAE). This condition affects approximately 1 in 50,000 individuals, with a global prevalence of 1 in 150,000. The increasing incidence of angioedema attacks, characterized by sudden swelling in various body regions, is leading to heightened awareness efforts by organizations like the US Hereditary Angioedema Association, which advocates for modern treatment options and support for patients. Recent surveys show that healthcare professionals have reported advancements in HAE management, with improved patient outcomes and satisfaction due to novel therapies. In India, an estimated 30,000-50,000 individuals suffer from HAE, predominantly treated by dermatologists, gastroenterologists, and clinical allergists.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hereditary Angioedema Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hereditary Angioedema Treatment Market Segmental Analysis

Global Hereditary Angioedema Treatment Market is segmented by Treatment, Route of Administration, Distribution Channel, End Use and region. Based on Treatment, the market is segmented into C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor and Others. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Others. Based on End Use, the market is segmented into Prophylaxis and On-demand. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hereditary Angioedema Treatment Market

The global hereditary angioedema treatment market is significantly driven by a heightened focus on advanced therapeutics aimed at managing these disorders. Researchers and manufacturers worldwide are diligently working to develop and enhance therapies for hereditary angioedema, as evidenced by numerous new medication applications for C1-esterase inhibitors, Bradykinin B2 receptor antagonists, and Kallikrein inhibitors targeting Types I, II, and III HAE. This surge in sophisticated treatment options, coupled with rising awareness and the increasing prevalence of rare diseases, has accelerated market growth. Recent approvals of innovative medications and a promising pipeline for future drug developments further bolster this expansion, alongside the growing impact of severe edema episodes linked to elevated estrogen levels and ACE inhibitor usage.

Restraints in the Global Hereditary Angioedema Treatment Market

The growth of the global hereditary angioedema treatment market is significantly hindered by the frequent misdiagnosis of the condition, often mistaken for common allergies, appendicitis, and irritable bowel syndrome. This misidentification stems from a widespread lack of awareness regarding hereditary angioedema (HAE), resulting in inadequate treatment for those affected. Consequently, many individuals suffering from HAE receive incorrect diagnoses, frequently being categorized under gastrointestinal disorders or non-allergic angioedema, thereby delaying appropriate care. This prevalent issue not only disrupts the treatment process for patients but also stifles advancements and expansion within the hereditary angioedema treatment market as a whole.

Market Trends of the Global Hereditary Angioedema Treatment Market

The Global Hereditary Angioedema (HAE) Treatment market is witnessing significant growth driven by increased awareness of rare conditions and the emergence of innovative therapies. Key catalysts include the introduction of novel therapeutics and pipeline medications, exemplified by recent products like Takhzyro (lanadelumab), which addresses prophylactic HAE treatment. A notable trend is the shift towards oral delivery methods, enhancing patient convenience and minimizing adverse effects compared to traditional treatments. As pharmaceutical companies explore the rare disease sector, the influx of new entrants with promising products suggests a competitive landscape poised for expansion. This dynamic environment is expected to further accelerate market growth and improve treatment accessibility for HAE patients globally.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Hereditary Angioedema Treatment Market Size by Treatment & CAGR (2025-2032)

Market Overview
C1-esterase inhibitor
Bradykinin B2 receptor antagonist
Kallikrein inhibitor
Others

Global Hereditary Angioedema Treatment Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Intravenous
Subcutaneous
Oral

Global Hereditary Angioedema Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Others

Global Hereditary Angioedema Treatment Market Size by End Use & CAGR (2025-2032)

Market Overview
Prophylaxis
On-demand

Global Hereditary Angioedema Treatment Market Size & CAGR (2025-2032)

North America (Treatment, Route of Administration, Distribution Channel, End Use)
- US
- Canada
Europe (Treatment, Route of Administration, Distribution Channel, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment, Route of Administration, Distribution Channel, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment, Route of Administration, Distribution Channel, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment, Route of Administration, Distribution Channel, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

CSL Behring (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pharming Group N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioCryst Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ionis Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KalVista Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Attune Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arrowhead Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMarin Pharmaceutical Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalyst Biosciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RUCONEST (Pharming Group N.V., Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Haegarda (CSL Limited, Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Firazyr (Shire plc, UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dyax Corp. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

遺伝性血管性浮腫治療薬市場規模、シェア、成長分析、治療法別、投与経路別、流通チャネル別、最終用途別、地域別 - 産業予測、2025-2032年

Hereditary Angioedema Treatment Market Size, Share, Growth Analysis, By Treatment, By Route of Administration, By Distribution Channel, By End Use, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

遺伝性血管性浮腫治療薬市場規模：治療別

遺伝性血管性浮腫治療薬市場規模：投与経路別

遺伝性血管性浮腫治療薬市場規模：流通チャネル別

遺伝性血管性浮腫治療薬市場規模：最終用途別

遺伝性血管性浮腫治療薬市場規模